Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide

Allergy, Asthma and Immunology Research

Volumn 2, Issue 1, 2010, Pages 55-58

  Kim, Joo Hee ^a   Moon, Jun Il ^a   Kim, Jeong Eun ^a   Choi, Gil Soon ^a   Park, Hae Sim ^a   Ye, Young Min ^a   Yim, Hyunee ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Cutaneous leukocytoclastic vasculitis; Pulmonary tuberculosis; Pyrazinamide; Rifampin

Indexed keywords

ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; D DIMER; ETHAMBUTOL; FIBRIN DEGRADATION PRODUCT; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; RIFODEX; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC VASCULITIS; ARTICLE; CASE REPORT; DRUG RECHALLENGE; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LEUKOCYTOCLASTIC VASCULITIS; LUNG TUBERCULOSIS; MALE; PURPURA; SKIN BIOPSY; SKIN DEFECT; THORAX RADIOGRAPHY;

EID: 77952770677     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2010.2.1.55     Document Type: Article

References (18)

1. Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003;30:161-173
2. Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008;30:352-369
3. Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009;123:1226-1236
4. Carvalho M, Dominoni RL, Senchechen D, Fernandes AF, Burigo IP, Doubrawa E. Cutaneous leukocytoclastic vasculitis accompanied by pulmonary tuberculosis. J Bras Pneumol 2008;34:745-748
5. Chan CH, Chong YW, Sun AJ, Hoheisel GB. Cutaneous vasculitis associated with tuberculosis and its treatment. Tubercle 1990;71:297-300.
6. Iredale JP, Sankaran R, Wathen CG. Cutaneous vasculitis associated with rifampin therapy. Chest 1989;96:215-216 (Pubitemid 19176452)
7. Kim HR, Park BH, Son J-Y, Jung JY, Ahn JR, Jung YS, Lim JE, Jung JW, Moon JA, Byun MK, Kim YS, Kim SK, Chang J, Lee KK, Park MS. A case of Henoch-Shönlein Purpura caused by rifampin. Tuberc Respir Dis 2008;65:116-120
8. Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ 1979;57:45-49
9. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med J Malaysia 2007;62:143-146
10. Parish WE, Rhodes EL. Bacterial antigens and aggregated gamma globulin in the lesions of nodular vasculitis. Br J Dermatol 1967;79:131-147
11. Johnson NM, McNicol MW, Burton-Kee EJ, Mowbray JF. Circulating immune complexes in tuberculosis. Thorax 1981;36:610-617
12. Barbagallo J, Tager P, Ingleton R, Hirsch RJ, Weinberg JM. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002;3:319-328
13. Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. Br Med J 1971;3:343-347
14. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-2030 (Pubitemid 26333539)
15. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477 (Pubitemid 37363354)
16. Kim SH, Lee BH, Lee KD, Park JS, Kim YS, Jee YK, Kim SH, Park HS, Min KU. The prevalence of adverse drug reactions to a short course anti-tuberculosis regimen. Korean J Med 2007;73:496-502.
17. Ribi C, Hauser C. Adverse reactions to pyrazinamide. Allergy 2002; 57:964-965
18. Perdu D, Lavaud F, Prevost A, Deschamps F, Cambie MP, Bongrain E, Barhoum K, Kalis B. Erythema multiforme due to pyrazinamide. Allergy 1996;51:340-342